Expert consensus on the clinical diagnosis and treatment path for diabetic macular edema in Zhejiang Province (2026)_Chinese Journal of Ocular Fundus Diseases

Authors：

 Zhejiang Provincial Professional Committee of Fundus Diseases

Corresponding author：

Zhejiang Provincial Professional Committee of Fundus Diseases, Email: chenzhiqing@zju.edu.cn

Keywords：

Diabetic macular edema; Individualized diagnosis and treatment; Evidence-based medicine; Expert consensus

DOI：

10.3760/cma.j.cn511434-20251220-00591

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic macular edema (DME) can occur at any stage of diabetic retinopathy and is the leading cause of vision loss in patients with diabetes. The primary therapeutic strategy for DME is to maximally maintain and improve patients' visual function. The development and progression of DME involve numerous risk factors and complex molecular mechanisms. Currently, there are multiple treatment options for DME in clinical practice, and different drugs and therapeutic regimens offer patients a variety of choices. However, in actual clinical practice, individual patient conditions, such as diabetes duration, glycemic control, age, severity of macular lesions, visual function needs, that pose new challenges for clinicians in formulating appropriate, individualized diagnosis and treatment plans. In such circumstances, the Zhejiang Provincial Professional Committee of Fundus Disease, focusing on key clinical issues in the diagnosis and treatment of DME, has developed this expert consensus based on the latest evidence-based medicine and the Delphi method, aiming to provide guidance and reference for the clinical diagnosis and treatment of DME.

Citation： Zhejiang Provincial Professional Committee of Fundus Diseases. Expert consensus on the clinical diagnosis and treatment path for diabetic macular edema in Zhejiang Province (2026). Chinese Journal of Ocular Fundus Diseases, 2026, 42(1): 12-25. doi: 10.3760/cma.j.cn511434-20251220-00591 Copy

1.	Hou X, Wang L, Zhu D, et al. Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in adults with diabetes in China[J/OL]. Nat Commun, 2023, 14(1): 4296[2023-07-18]. https://pubmed.ncbi.nlm.nih.gov/37463878/. DOI: 10.1038/s41467-023-39864-w.
2.	Sakini ASA, Hamid AK, Alkhuzaie ZA, et al. Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights[J/OL]. Int J Retina Vitreous, 2024, 10(1): 83[2024-10-28]. https://pubmed.ncbi.nlm.nih.gov/39468614/. DOI: 10.1186/s40942-024-00603-y.
3.	中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)——基于循证医学修订[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Retinal Disease Group of Ophthalmology Branch, Chinese Medical Association, Retinal Disease Group of Ophthalmology Physicians Branch, Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
4.	Boscia F, Veritti D, Iaculli C, et al. Management of treatment-naïve diabetic macular edema patients: review of real-world clinical data[J]. Eur J Ophthalmol, 2024, 34(6): 1675-1694. DOI: 10.1177/11206721241237069.
5.	Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64(4): 401-406. DOI: 10.1016/j.jclinepi.2010.07.015.
6.	Early Treatment Diabetic Retinopathy Study. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group[J]. Arch Ophthalmol, 1985, 103(12): 1796-1806.
7.	Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
8.	中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Retinal Disease Group, Ophthalmology Society of Chinese Medical Association. Clinical diagnosis and treatment guidelines for diabetic retinopathy in China (2014)[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
9.	Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
10.	Baker CW, Glassman AR, Beaulieu WT, et al. DRCR Retina Network. Effect of initial management with Aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial[J]. JAMA, 2019, 321(19): 1880-1894. DOI: 10.1001/jama.2019.5790.
11.	Busch C, Fraser-Bell S, Zur D, et al. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study[J]. Acta Diabetol, 2019, 56(7): 777-784. DOI: 10.1007/s00592-019-01310-z.
12.	Feldman S, Basra J, Lawani A, et al. Subthreshold micropulse laser for eyes: with center involving diabetic macular edema with good visual acuity: the PULSE Study, a randomized clinical trial[J]. Ophthalmic Surg Lasers Imaging Retina, 2025, 56(2): 86-93. DOI: 10.3928/23258160-20240924-03.
13.	Zafar S, Smith K, Boland MV, et al. Real-world outcomes among eyes with center-involving diabetic macular edema and good visual acuity[J]. Curr Eye Res, 2020, 45(7): 879-887. DOI: 10.1080/02713683.2019.1703007.
14.	Hentati F, Melo AGR, Greenlee TE, et al. Management of patients with DME with good visual acuity in routine clinical practice[J]. Ophthalmic Surg Lasers Imaging Retina, 2021, 52(5): 247-256. DOI: 10.3928/23258160-20210429-02.
15.	Busch C, Okada M, Zur D, et al. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity[J/OL]. Acta Ophthalmol, 2020, 98(7): e801-e806[2020-03-01]. https://pubmed.ncbi.nlm.nih.gov/32115886/. DOI: 10.1111/aos.14390.
16.	Chhablani J, Wong K, Tan GS, et al. Diabetic macular edema management in Asian population: expert panel consensus guidelines[J]. Asia Pac J Ophthalmol (Phila), 2020, 9(5): 426-434. DOI: 10.1097/APO.0000000000000312.
17.	Glassman AR, Wells JA 3rd, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)[J]. Ophthalmology, 2020, 127(9): 1201-1210. DOI: 10.1016/j.ophtha.2020.03.021.
18.	Aldokhail LS, Alhadlaq AM, Alaradi LM, et al. Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review[J]. Clin Ophthalmol, 2024, 18: 3837-3851. DOI: 10.2147/OPTH.S489114.
19.	Mahapatra SK, Parhi A, Shree P, et al. Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema[J]. Indian J Ophthalmol, 2024, 72(Suppl 1): S106-110. DOI: 10.4103/IJO.IJO_767_23.
20.	Chakraborty S, Ganguly S, Sheth JU. Role of intravitreal dexamethasone implant in the management of treatment-naive diabetic macular edema: a pre-cataract surgical approach for patients with systemic contraindications to anti-VEGF therapy[J]. Clin Ophthalmol, 2024, 18: 227-233. DOI: 10.2147/OPTH.S449250.
21.	Ceravolo I, Oliverio GW, Alibrandi A, et al. The application of structural retinal biomarkers to evaluate the effect of intravitreal ranibizumab and dexamethasone intravitreal implant on treatment of diabetic macular edema[J/OL]. Diagnostics (Basel), 2020, 10(6): 413[2020-06-17]. https://pubmed.ncbi.nlm.nih.gov/32560526/. DOI: 10.3390/diagnostics10060413.
22.	Bolukbasi S, Cakir A, Erden B, et al. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema[J]. Cutan Ocul Toxicol, 2019, 38(4): 401-405. DOI: 10.1080/15569527.2019.1657884.
23.	Chakraborty S, Sheth JU. Comparative analysis of intravitreal dexamethasone implant (Ozurdex) and brolucizumab injection in the treatment of diabetic macular edema with hyperreflective intraretinal dots: a retrospective study[J]. Clin Ophthalmol, 2024, 18: 2897-2905. DOI: 10.2147/OPTH.S484731.
24.	Mehta H, Fraser-Bell S, Yeung A, et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial[J]. Br J Ophthalmol, 2016, 100(7): 1000-1004. DOI: 10.1136/bjophthalmol-2015-307797.
25.	Bilgic A, Sudhalkar A, Kodjikian L, et al. Pro re nata dexamethasone implant for treatment-naive phakic eyes with diabetic macular edema: a prospective study[J]. Ophthalmol Retina, 2019, 3(11): 929-937. DOI: 10.1016/j.oret.2019.05.027.
26.	Yuan Q, Liu Y, Gou Y, et al. Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: a systematic review and meta-analysis[J/OL]. Front Pharmacol, 2022, 13: 1029584[2022-12-01]. https://pubmed.ncbi.nlm.nih.gov/36532786/. DOI: 10.3389/fphar.2022.1029584.
27.	李璐瑶, 李静, 李艳, 等. 地塞米松玻璃体内植入剂对不同糖尿病性黄斑水肿的疗效与安全性评价[J]. 中华眼科杂志, 2023, 59(5): 398-403. DOI: 10.3760/cma.j.cn112142-20220722-00355.Li LY, Li J, Li Y, et al. Efficacy and safety of intravitreal dexamethasone implant in diabetic macular edema patients with and without prior vitrectomy: a retrospective cohort study[J]. Chin J Ophthalmol, 2023, 59(5): 398-403. DOI: 10.3760/cma.j.cn112142-20220722-00355.
28.	Liang Y, Yan B, Xie M, et al. One-month outcomes of intravitreal anti-VEGF vs. dexamethasone implant in the treatment of diabetic macular edema in vitrectomized eyes[J/OL]. Front Med (Lausanne), 2022, 9: 895220[2022-06-14]. https://pubmed.ncbi.nlm.nih.gov/35774995/. DOI: 10.3389/fmed.2022.895220.
29.	Srinivasan R, Sharma U, George R, et al. Intraocular pressure changes after dexamethasone implant in patients with glaucoma and steroid responders[J]. Retina, 2019, 39(1): 157-162. DOI: 10.1097/IAE.0000000000001924.
30.	Goñi FJ, Barton K, Dias JA, et al. Intravitreal corticosteroid implantation in diabetic macular edema: updated European consensus guidance on monitoring and managing intraocular pressure[J]. Ophthalmol Ther, 2022, 11(1): 15-34. DOI: 10.1007/s40123-021-00427-1.
31.	Hernández-Bel L, Cervera-Taulet E, Navarro-Palop C, et al. Sequential dexamethasone and aflibercept treatment in patients with diabetic macular edema: structural and functional outcomes at 52 weeks[J]. Ophthalmologica, 2019, 241(2): 98-104. DOI: 10.1159/000489345.
32.	Ozsaygılı C, Bayram N. Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?[J/OL]. Int Ophthalmol, 2024, 44(1): 51[2024-02-09]. https://pubmed.ncbi.nlm.nih.gov/38336941/. DOI: 10.1007/s10792-024-02963-8.
33.	Kaya M, Atas F, Kocak N, et al. Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: the month 24 results from simultaneously double protocol[J]. Curr Eye Res, 2023, 48(5): 498-505. DOI: 10.1080/02713683.2023.2168013.
34.	Singh RP, Tabano D, Kuo BL, et al. How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema[J/OL]. BMC Ophthalmol, 2024, 24(1): 552[2024-12-30]. https://pubmed.ncbi.nlm.nih.gov/39736584/. DOI: 10.1186/s12886-024-03797-9.
35.	Ren F, Zhang X, Gong H, et al. Two different initial treatment regimens of conbercept in diabetic macular edema: 12-month results from a multicenter randomized controlled study[J/OL]. Photodiagnosis Photodyn Ther, 2023, 44: 103745[2023-08-09]. https://pubmed.ncbi.nlm.nih.gov/37567331/. DOI: 10.1016/j.pdpdt.2023.103745.
36.	Cakir A, Erden B, Bolukbasi S, et al. Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results[J]. Arq Bras Oftalmol, 2020, 83(5): 396-401. DOI: 10.5935/0004-2749.20200078.
37.	吴乔伟, 黄珍, 闫明, 等. 康柏西普不同给药方案治疗糖尿病黄斑水肿的疗效对比[J]. 中华眼底病杂志, 2022, 38(1): 40-48. DOI: 10.3760/cma.j.cn511434-20211123-00653.Wu QW, Huang Z, Yan M, et al. Comparison of different loading doses followed by pro re nata regimens of intravitreal conbercept for diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 40-48. DOI: 10.3760/cma.j.cn511434-20211123-00653.
38.	Sarohia GS, Nanji K, Khan M, et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2, 346 eyes[J]. Surv Ophthalmol, 2022, 67(5): 1346-1363. DOI: 10.1016/j.survophthal.2022.04.003.
39.	Garweg JG, Štefanickova J, Hoyng C, et al. Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial[J]. Adv Ther, 2022, 39(6): 2701-2716. DOI: 10.1007/s12325-022-02119-z.
40.	Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study[J]. Br J Ophthalmol, 2016, 100(6): 787-795. DOI: 10.1136/bjophthalmol-2015-307249.
41.	Yozgat Z, Isik MU, Sabaner MC. One-year outcomes of aflibercept in treat-and-extend versus pro re nata regimens for bevacizumab-resistant diabetic macular edema: a real-world study[J]. Ophthalmol Ther, 2025, 14(1): 169-181. DOI: 10.1007/s40123-024-01067-x.
42.	Lai TT, Chen TC, Yang CH, et al. Treatt-and-extend vs. pro re nata regimen of ranibizumab for diabetic macular edema-a two-year matched comparative study[J/OL]. Front Med (Lausanne), 2022, 8: 781421[2022-01-25]. https://pubmed.ncbi.nlm.nih.gov/35145975/. DOI: 10.3389/fmed.2021.781421.
43.	Cao J, You K, Jin K, et al. Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method[J/OL]. Acta Ophthalmol, 2021, 99(1): e19-e27[2020-06-22]. https://pubmed.ncbi.nlm.nih.gov/32573116/. DOI: 10.1111/aos.14514.
44.	Gunay BO, Erdogan G, Akalin I, et al. Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?[J/OL]. Arq Bras Oftalmol, 2023, 87(6): e20220228[2023-10-20]. https://pubmed.ncbi.nlm.nih.gov/37878875/. DOI: 10.5935/0004-2749.2022-0228.
45.	Maeda S, Sugimoto M, Tenma Y, et al. Response to initial anti-vascular endothelial growth factor for diabetic macular edema is significantly correlated with response to third consecutive monthly injection[J/OL]. J Clin Med, 2022, 11(21): 6416[2022-10-29]. https://pubmed.ncbi.nlm.nih.gov/36362644/. DOI: 10.3390/jcm11216416.
46.	Shah AR, Yonekawa Y, Todorich B, et al. Prediction of anti-VEGF response in diabetic macular edema after 1 injection[J]. J Vitreoretin Dis, 2017, 1(3): 169-174. DOI: 10.1177/2474126416682569.
47.	Tahmasebi A, Ebrahimiadib N, Niyousha M, et al. Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis[J]. Graefe's Arch Clin Exp Ophthalmol, 2025, 263(10): 2693-2707. DOI: 10.1007/s00417-025-06878-7.
48.	Liu Y, Cheng J, Gao Y, et al. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis[J/OL]. Ann Transl Med, 2020, 8(6): 382[2020-03-01]. https://pubmed.ncbi.nlm.nih.gov/32355826/. DOI: 10.21037/atm.2020.02.04.
49.	Wood EH, Karth PA, Moshfeghi DM, et al. Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab[J]. Ophthalmic Surg Lasers Imaging Retina, 2015, 46(9): 950-954. DOI: 10.3928/23258160-20151008-08.
50.	Pichi F, Abdi A, Aljneibi S, et al. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema[J/OL]. Int Ophthalmol, 2024, 44(1): 275[2024-06-25]. https://pubmed.ncbi.nlm.nih.gov/38916818/. DOI: 10.1007/s10792-024-03226-2.
51.	Huber KL, Stino H, Steiner I, et al. Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema[J/OL]. Invest Ophthalmol Vis Sci, 2024, 65(14): 46[2024-12-02]. https://pubmed.ncbi.nlm.nih.gov/39739347/. DOI: 10.1167/iovs.65.14.46.
52.	Madjedi K, Pereira A, Ballios BG, et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review[J]. Surv Ophthalmol, 2022, 67(5): 1364-1372. DOI: 10.1016/j.survophthal.2022.04.001.
53.	Ohara H, Harada Y, Hiyama T, et al. Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept[J/OL]. Medicina (Kaunas), 2023, 59(6): 1125[2023-06-11]. https://pubmed.ncbi.nlm.nih.gov/37374329/. DOI: 10.3390/medicina59061125.
54.	Sorour OA, Liu K, Mehta N, et al. Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema[J/OL]. Int J Retina Vitreous, 2020, 6: 17[2020-06-08]. https://pubmed.ncbi.nlm.nih.gov/32523776/. DOI: 10.1186/s40942-020-00220-5.
55.	Wolfrum P, Böhm EW, Lorenz K, et al. Short-term clinical outcomes of patients with diabetic macular edema following a therapy switch to Faricimab[J/OL]. J Clin Med, 2024, 13(15): 4508[2024-08-01]. https://pubmed.ncbi.nlm.nih.gov/39124774/. DOI: 10.3390/jcm13154508.
56.	Cao C, Yu G, Deng Z. Early versus late switch to an intravitreal dexamethasone implant after failed anti-VEGF therapy for diabetic macular edema: a systematic review and meta-analysis[J]. Ophthalmic Res, 2025, 68(1): 360-371. DOI: 10.1159/000546682.
57.	Busch C, Zur D, Fraser-Bell S, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema[J]. Acta Diabetol, 2018, 55(8): 789-796. DOI: 10.1007/s00592-018-1151-x.
58.	Ruiz-Medrano J, Rodríguez-Leor R, Almazán E, et al. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: early versus late switch[J]. Eur J Ophthalmol, 2021, 31(3): 1135-1145. DOI: 10.1177/1120672120929960.
59.	Kavoussi S, Nezgoda J, Chhablani J, et al. Early switch to the dexamethasone implant after sub-optimal response to anti-VEGF therapy for diabetic macular edema[J]. Invest Ophthalmol Vis Sci, 2021, 62(8): 1053.
60.	邓爱萍, 田润, 熊成, 等. 地塞米松玻璃体内植入剂早期联合康柏西普在抗血管内皮生长因子治疗反应不佳糖尿病性黄斑水肿中的应用[J]. 眼科新进展, 2023, 43(9): 722-726. DOI: 10.13389/j.cnki.rao.2023.0145.Deng AP, Tian R, Xiong C, et al. Application of intravitreal dexamethasone implant combined with conbercept in the treatment of diabetic macular edema with poor response to anti-vascular endothelial growth factor therapy[J]. Rec Adv Ophthalmol, 2023, 43(9): 722-726. DOI: 10.13389/j.cnki.rao.2023.0145.
61.	Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(10): 1904-1914. DOI: 10.1016/j.ophtha.2014.04.024.
62.	Fraser-Bell S, Kang HK, Mitchell P, et al. Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study[J]. Br J Ophthalmol, 2023, 107(1): 72-78. DOI: 10.1136/bjophthalmol-2021-319070.
63.	Kodjikian L, Baillif S, Couturier A, et al. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study[J]. Eur J Ophthalmol, 2022, 32(5): 2845-2856. DOI: 10.1177/11206721211052852.
64.	Rodríguez-Valdés PJ, Rehak M, Zur D, et al. GRAding of functional and anatomical response to dexamethasone implant in patients with diabetic macular edema: GRADE-DME Study[J/OL]. Sci Rep, 2021, 11(1): 4738[2021-02-06]. https://pubmed.ncbi.nlm.nih.gov/33637772/. DOI: 10.1038/s41598-020-79288-w.
65.	Al-Khersan H, Hariprasad SM, Chhablani J, et al. Early response to intravitreal dexamethasone implant therapy in diabetic macular edema may predict visual outcome[J]. Am J Ophthalmol, 2017, 184: 121-128. DOI: 10.1016/j.ajo.2017.10.004.
66.	Rosenblatt A, Udaondo P, Cunha-Vaz J, et al. ARTES Study Group. A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME Registry Study[J]. Ophthalmology, 2020, 127(3): 377-393. DOI: 10.1016/j.ophtha.2019.10.005.
67.	Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(1): 29-38. DOI: 10.1001/jamaophthalmol.2017.4914.
68.	Limon U. Early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema[J]. J Fr Ophtalmol, 2021, 44(6): 849-854. DOI: 10.1016/j.jfo.2020.08.033.
69.	Lin TC, Chung YC, Hsu TK, et al. Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema[J]. Acta Diabetol, 2022, 59(4): 501-508. DOI: 10.1007/s00592-021-01824-5.
70.	Zhao X, Lin Z, Long T, et al. Early combined conbercept and dexamethasone implant therapy for diabetic macular edema[J/OL]. Int Ophthalmol, 2025, 45(1): 267[2025-06-27]. https://pubmed.ncbi.nlm.nih.gov/40576850/. DOI: 10.1007/s10792-025-03646-8.
71.	Chen J, Wang H, Qiu W. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: a systematic review and network meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1096105[2023-02-02]. https://pubmed.ncbi.nlm.nih.gov/36817588/. DOI: 10.3389/fendo.2023.1096105.
72.	Yang X, Cao Y, Cao X, et al. Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: a Bayesian network meta-analysis[J]. Diabetes Obes Metab, 2025, 27(5): 2679-2689. DOI: 10.1111/dom.16270.
73.	Hatano M, Wakuta M, Yamamoto K, et al. Use of ranibizumab for evaluating focal laser combination therapy for refractory diabetic macular edema patients: an exploratory study on the RELAND trials[J/OL]. Sci Rep. 2023, 13(1): 22965[2023-12-27]. https://pubmed.ncbi.nlm.nih.gov/38151499/. DOI: 10.1038/s41598-023-48665-6.
74.	Lubis PM, Prabaniswara MP, Victor AA. Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: systematic review[J]. Indian J Ophthalmol, 2023, 71(11): 3448-3453. DOI: 10.4103/IJO.IJO_519_23.
75.	Hosoya H, Ueta T, Hirasawa K, et al. Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis[J]. Graefe's Arch Clin Exp Ophthalmol, 2024, 262(10): 3073-3083. DOI: 10.1007/s00417-024-06460-7.
76.	Xu D, Zhu T, Huang L, et al. Clinical efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a meta-analysis[J/OL]. Medicine (Baltimore), 2024, 103(5): e34583[2024-02-02]. https://pubmed.ncbi.nlm.nih.gov/38306515/. DOI: 10.1097/MD.0000000000034583.
77.	Ma CC, Chen PH, Hsieh YH. Optimizing diabetic macular edema treatment: a meta-analysis of subthreshold micropulse laser and anti-vascular endothelial growth factor combination therapy[J/OL]. J Clin Med, 2024, 13(16): 4782[2024-08-14]. https://pubmed.ncbi.nlm.nih.gov/39200924/. DOI: 10.3390/jcm13164782.
78.	Jiang Y, He W, Qi S. Evaluating the efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2025, 16: 1553311[2025-03-28]. https://pubmed.ncbi.nlm.nih.gov/40225323/. DOI: 10.3389/fendo.2025.1553311.
79.	Çıtırık M. Nondamaging retinal laser therapy in recurrent diabetic macular edema after anti-VEGF injections[J]. Turk J Med Sci, 2021, 51(5): 2616-2620. DOI: 10.3906/sag-2007-304.
80.	Elhamid AHA. Combined intravitreal dexamethasone implant and micropulse yellow laser for treatment of anti-VEGF resistant diabetic macular edema[J]. Open Ophthalmol J, 2017, 11: 164-172. DOI: 10.2174/1874364101711010164.
81.	Wang M, Luan R, Liu B, et al. The anatomic and functional outcomes of ozurdex-aided vitrectomy in proliferative diabetic retinopathy[J]. Diabetes Metab Syndr Obes, 2024, 17: 1199-1213. DOI: 10.2147/DMSO.S445607.
82.	Altun A, Kanar HS, Aki SF, et al. Effectiveness and safety of coadministration of intravitreal dexamethasone implant and silicone oil endotamponade for proliferative diabetic retinopathy with tractional diabetic macular edema[J]. J Ocul Pharmacol Ther, 2021, 37(2): 131-137. DOI: 10.1089/jop.2020.0079.
83.	Kim KT, Jang JW, Kang SW, et al. Vitrectomy combined with intraoperative dexamethasone implant for the management of refractory diabetic macular edema[J]. Korean J Ophthalmol, 2019, 33(3): 249-258. DOI: 10.3341/kjo.2018.0100.
84.	Jung YH, Lee Y. Efficacy of vitrectomy combined with an intraoperative dexamethasone implant in refractory diabetic macular edema[J]. Acta Diabetol, 2019, 56(6): 691-696. DOI: 10.1007/s00592-019-01305-w.
85.	惠延年. 糖尿病视网膜病: 糖尿病视网膜病变重新定义的术语[J]. 中华眼底病杂志, 2026, 42(1): 3-7. DOI: 10.3760/cma.j.cn511434-20251120-00515.Hui YN. Diabetic retinal disease: a redefined term for diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2026, 42(1): 3-7. DOI: 10.3760/cma.j.cn511434-20251120-00515.
86.	Pei X, Li Z. Narrative review of comprehensive management strategies for diabetic retinopathy: interdisciplinary approaches and future perspectives[J/OL]. BMJ Public Health, 2025, 3(1): e001353[2025-01-16]. https://pubmed.ncbi.nlm.nih.gov/40017934/. DOI: 10.1136/bmjph-2024-001353.
87.	Strain WD, Cos X, Prünte C. Considerations for management of patients with diabetic macular edema: optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration[J]. Diabetes Res Clin Pract, 2017, 126: 1-9. DOI: 10.1016/j.diabres.2017.01.013.

1. Hou X, Wang L, Zhu D, et al. Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in adults with diabetes in China[J/OL]. Nat Commun, 2023, 14(1): 4296[2023-07-18]. https://pubmed.ncbi.nlm.nih.gov/37463878/. DOI: 10.1038/s41467-023-39864-w.
2. Sakini ASA, Hamid AK, Alkhuzaie ZA, et al. Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights[J/OL]. Int J Retina Vitreous, 2024, 10(1): 83[2024-10-28]. https://pubmed.ncbi.nlm.nih.gov/39468614/. DOI: 10.1186/s40942-024-00603-y.
3. 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2022年)——基于循证医学修订[J]. 中华眼底病杂志, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.Retinal Disease Group of Ophthalmology Branch, Chinese Medical Association, Retinal Disease Group of Ophthalmology Physicians Branch, Chinese Medical Doctor Association. Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)[J]. Chin J Ocul Fundus Dis, 2023, 39(2): 99-124. DOI: 10.3760/cma.j.cn511434-20230110-00018.
4. Boscia F, Veritti D, Iaculli C, et al. Management of treatment-naïve diabetic macular edema patients: review of real-world clinical data[J]. Eur J Ophthalmol, 2024, 34(6): 1675-1694. DOI: 10.1177/11206721241237069.
5. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64(4): 401-406. DOI: 10.1016/j.jclinepi.2010.07.015.
6. Early Treatment Diabetic Retinopathy Study. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group[J]. Arch Ophthalmol, 1985, 103(12): 1796-1806.
7. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
8. 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Retinal Disease Group, Ophthalmology Society of Chinese Medical Association. Clinical diagnosis and treatment guidelines for diabetic retinopathy in China (2014)[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
9. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
10. Baker CW, Glassman AR, Beaulieu WT, et al. DRCR Retina Network. Effect of initial management with Aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial[J]. JAMA, 2019, 321(19): 1880-1894. DOI: 10.1001/jama.2019.5790.
11. Busch C, Fraser-Bell S, Zur D, et al. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study[J]. Acta Diabetol, 2019, 56(7): 777-784. DOI: 10.1007/s00592-019-01310-z.
12. Feldman S, Basra J, Lawani A, et al. Subthreshold micropulse laser for eyes: with center involving diabetic macular edema with good visual acuity: the PULSE Study, a randomized clinical trial[J]. Ophthalmic Surg Lasers Imaging Retina, 2025, 56(2): 86-93. DOI: 10.3928/23258160-20240924-03.
13. Zafar S, Smith K, Boland MV, et al. Real-world outcomes among eyes with center-involving diabetic macular edema and good visual acuity[J]. Curr Eye Res, 2020, 45(7): 879-887. DOI: 10.1080/02713683.2019.1703007.
14. Hentati F, Melo AGR, Greenlee TE, et al. Management of patients with DME with good visual acuity in routine clinical practice[J]. Ophthalmic Surg Lasers Imaging Retina, 2021, 52(5): 247-256. DOI: 10.3928/23258160-20210429-02.
15. Busch C, Okada M, Zur D, et al. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity[J/OL]. Acta Ophthalmol, 2020, 98(7): e801-e806[2020-03-01]. https://pubmed.ncbi.nlm.nih.gov/32115886/. DOI: 10.1111/aos.14390.
16. Chhablani J, Wong K, Tan GS, et al. Diabetic macular edema management in Asian population: expert panel consensus guidelines[J]. Asia Pac J Ophthalmol (Phila), 2020, 9(5): 426-434. DOI: 10.1097/APO.0000000000000312.
17. Glassman AR, Wells JA 3rd, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)[J]. Ophthalmology, 2020, 127(9): 1201-1210. DOI: 10.1016/j.ophtha.2020.03.021.
18. Aldokhail LS, Alhadlaq AM, Alaradi LM, et al. Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review[J]. Clin Ophthalmol, 2024, 18: 3837-3851. DOI: 10.2147/OPTH.S489114.
19. Mahapatra SK, Parhi A, Shree P, et al. Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema[J]. Indian J Ophthalmol, 2024, 72(Suppl 1): S106-110. DOI: 10.4103/IJO.IJO_767_23.
20. Chakraborty S, Ganguly S, Sheth JU. Role of intravitreal dexamethasone implant in the management of treatment-naive diabetic macular edema: a pre-cataract surgical approach for patients with systemic contraindications to anti-VEGF therapy[J]. Clin Ophthalmol, 2024, 18: 227-233. DOI: 10.2147/OPTH.S449250.
21. Ceravolo I, Oliverio GW, Alibrandi A, et al. The application of structural retinal biomarkers to evaluate the effect of intravitreal ranibizumab and dexamethasone intravitreal implant on treatment of diabetic macular edema[J/OL]. Diagnostics (Basel), 2020, 10(6): 413[2020-06-17]. https://pubmed.ncbi.nlm.nih.gov/32560526/. DOI: 10.3390/diagnostics10060413.
22. Bolukbasi S, Cakir A, Erden B, et al. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema[J]. Cutan Ocul Toxicol, 2019, 38(4): 401-405. DOI: 10.1080/15569527.2019.1657884.
23. Chakraborty S, Sheth JU. Comparative analysis of intravitreal dexamethasone implant (Ozurdex) and brolucizumab injection in the treatment of diabetic macular edema with hyperreflective intraretinal dots: a retrospective study[J]. Clin Ophthalmol, 2024, 18: 2897-2905. DOI: 10.2147/OPTH.S484731.
24. Mehta H, Fraser-Bell S, Yeung A, et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial[J]. Br J Ophthalmol, 2016, 100(7): 1000-1004. DOI: 10.1136/bjophthalmol-2015-307797.
25. Bilgic A, Sudhalkar A, Kodjikian L, et al. Pro re nata dexamethasone implant for treatment-naive phakic eyes with diabetic macular edema: a prospective study[J]. Ophthalmol Retina, 2019, 3(11): 929-937. DOI: 10.1016/j.oret.2019.05.027.
26. Yuan Q, Liu Y, Gou Y, et al. Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: a systematic review and meta-analysis[J/OL]. Front Pharmacol, 2022, 13: 1029584[2022-12-01]. https://pubmed.ncbi.nlm.nih.gov/36532786/. DOI: 10.3389/fphar.2022.1029584.
27. 李璐瑶, 李静, 李艳, 等. 地塞米松玻璃体内植入剂对不同糖尿病性黄斑水肿的疗效与安全性评价[J]. 中华眼科杂志, 2023, 59(5): 398-403. DOI: 10.3760/cma.j.cn112142-20220722-00355.Li LY, Li J, Li Y, et al. Efficacy and safety of intravitreal dexamethasone implant in diabetic macular edema patients with and without prior vitrectomy: a retrospective cohort study[J]. Chin J Ophthalmol, 2023, 59(5): 398-403. DOI: 10.3760/cma.j.cn112142-20220722-00355.
28. Liang Y, Yan B, Xie M, et al. One-month outcomes of intravitreal anti-VEGF vs. dexamethasone implant in the treatment of diabetic macular edema in vitrectomized eyes[J/OL]. Front Med (Lausanne), 2022, 9: 895220[2022-06-14]. https://pubmed.ncbi.nlm.nih.gov/35774995/. DOI: 10.3389/fmed.2022.895220.
29. Srinivasan R, Sharma U, George R, et al. Intraocular pressure changes after dexamethasone implant in patients with glaucoma and steroid responders[J]. Retina, 2019, 39(1): 157-162. DOI: 10.1097/IAE.0000000000001924.
30. Goñi FJ, Barton K, Dias JA, et al. Intravitreal corticosteroid implantation in diabetic macular edema: updated European consensus guidance on monitoring and managing intraocular pressure[J]. Ophthalmol Ther, 2022, 11(1): 15-34. DOI: 10.1007/s40123-021-00427-1.
31. Hernández-Bel L, Cervera-Taulet E, Navarro-Palop C, et al. Sequential dexamethasone and aflibercept treatment in patients with diabetic macular edema: structural and functional outcomes at 52 weeks[J]. Ophthalmologica, 2019, 241(2): 98-104. DOI: 10.1159/000489345.
32. Ozsaygılı C, Bayram N. Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?[J/OL]. Int Ophthalmol, 2024, 44(1): 51[2024-02-09]. https://pubmed.ncbi.nlm.nih.gov/38336941/. DOI: 10.1007/s10792-024-02963-8.
33. Kaya M, Atas F, Kocak N, et al. Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: the month 24 results from simultaneously double protocol[J]. Curr Eye Res, 2023, 48(5): 498-505. DOI: 10.1080/02713683.2023.2168013.
34. Singh RP, Tabano D, Kuo BL, et al. How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema[J/OL]. BMC Ophthalmol, 2024, 24(1): 552[2024-12-30]. https://pubmed.ncbi.nlm.nih.gov/39736584/. DOI: 10.1186/s12886-024-03797-9.
35. Ren F, Zhang X, Gong H, et al. Two different initial treatment regimens of conbercept in diabetic macular edema: 12-month results from a multicenter randomized controlled study[J/OL]. Photodiagnosis Photodyn Ther, 2023, 44: 103745[2023-08-09]. https://pubmed.ncbi.nlm.nih.gov/37567331/. DOI: 10.1016/j.pdpdt.2023.103745.
36. Cakir A, Erden B, Bolukbasi S, et al. Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results[J]. Arq Bras Oftalmol, 2020, 83(5): 396-401. DOI: 10.5935/0004-2749.20200078.
37. 吴乔伟, 黄珍, 闫明, 等. 康柏西普不同给药方案治疗糖尿病黄斑水肿的疗效对比[J]. 中华眼底病杂志, 2022, 38(1): 40-48. DOI: 10.3760/cma.j.cn511434-20211123-00653.Wu QW, Huang Z, Yan M, et al. Comparison of different loading doses followed by pro re nata regimens of intravitreal conbercept for diabetic macular edema[J]. Chin J Ocul Fundus Dis, 2022, 38(1): 40-48. DOI: 10.3760/cma.j.cn511434-20211123-00653.
38. Sarohia GS, Nanji K, Khan M, et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2, 346 eyes[J]. Surv Ophthalmol, 2022, 67(5): 1346-1363. DOI: 10.1016/j.survophthal.2022.04.003.
39. Garweg JG, Štefanickova J, Hoyng C, et al. Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first year: VIOLET, a prospective randomized trial[J]. Adv Ther, 2022, 39(6): 2701-2716. DOI: 10.1007/s12325-022-02119-z.
40. Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study[J]. Br J Ophthalmol, 2016, 100(6): 787-795. DOI: 10.1136/bjophthalmol-2015-307249.
41. Yozgat Z, Isik MU, Sabaner MC. One-year outcomes of aflibercept in treat-and-extend versus pro re nata regimens for bevacizumab-resistant diabetic macular edema: a real-world study[J]. Ophthalmol Ther, 2025, 14(1): 169-181. DOI: 10.1007/s40123-024-01067-x.
42. Lai TT, Chen TC, Yang CH, et al. Treatt-and-extend vs. pro re nata regimen of ranibizumab for diabetic macular edema-a two-year matched comparative study[J/OL]. Front Med (Lausanne), 2022, 8: 781421[2022-01-25]. https://pubmed.ncbi.nlm.nih.gov/35145975/. DOI: 10.3389/fmed.2021.781421.
43. Cao J, You K, Jin K, et al. Prediction of response to anti-vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography-based machine learning method[J/OL]. Acta Ophthalmol, 2021, 99(1): e19-e27[2020-06-22]. https://pubmed.ncbi.nlm.nih.gov/32573116/. DOI: 10.1111/aos.14514.
44. Gunay BO, Erdogan G, Akalin I, et al. Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?[J/OL]. Arq Bras Oftalmol, 2023, 87(6): e20220228[2023-10-20]. https://pubmed.ncbi.nlm.nih.gov/37878875/. DOI: 10.5935/0004-2749.2022-0228.
45. Maeda S, Sugimoto M, Tenma Y, et al. Response to initial anti-vascular endothelial growth factor for diabetic macular edema is significantly correlated with response to third consecutive monthly injection[J/OL]. J Clin Med, 2022, 11(21): 6416[2022-10-29]. https://pubmed.ncbi.nlm.nih.gov/36362644/. DOI: 10.3390/jcm11216416.
46. Shah AR, Yonekawa Y, Todorich B, et al. Prediction of anti-VEGF response in diabetic macular edema after 1 injection[J]. J Vitreoretin Dis, 2017, 1(3): 169-174. DOI: 10.1177/2474126416682569.
47. Tahmasebi A, Ebrahimiadib N, Niyousha M, et al. Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis[J]. Graefe's Arch Clin Exp Ophthalmol, 2025, 263(10): 2693-2707. DOI: 10.1007/s00417-025-06878-7.
48. Liu Y, Cheng J, Gao Y, et al. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis[J/OL]. Ann Transl Med, 2020, 8(6): 382[2020-03-01]. https://pubmed.ncbi.nlm.nih.gov/32355826/. DOI: 10.21037/atm.2020.02.04.
49. Wood EH, Karth PA, Moshfeghi DM, et al. Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab[J]. Ophthalmic Surg Lasers Imaging Retina, 2015, 46(9): 950-954. DOI: 10.3928/23258160-20151008-08.
50. Pichi F, Abdi A, Aljneibi S, et al. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema[J/OL]. Int Ophthalmol, 2024, 44(1): 275[2024-06-25]. https://pubmed.ncbi.nlm.nih.gov/38916818/. DOI: 10.1007/s10792-024-03226-2.
51. Huber KL, Stino H, Steiner I, et al. Real-world outcomes after switch from aflibercept to faricimab in eyes with diabetic macular edema[J/OL]. Invest Ophthalmol Vis Sci, 2024, 65(14): 46[2024-12-02]. https://pubmed.ncbi.nlm.nih.gov/39739347/. DOI: 10.1167/iovs.65.14.46.
52. Madjedi K, Pereira A, Ballios BG, et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review[J]. Surv Ophthalmol, 2022, 67(5): 1364-1372. DOI: 10.1016/j.survophthal.2022.04.001.
53. Ohara H, Harada Y, Hiyama T, et al. Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept[J/OL]. Medicina (Kaunas), 2023, 59(6): 1125[2023-06-11]. https://pubmed.ncbi.nlm.nih.gov/37374329/. DOI: 10.3390/medicina59061125.
54. Sorour OA, Liu K, Mehta N, et al. Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema[J/OL]. Int J Retina Vitreous, 2020, 6: 17[2020-06-08]. https://pubmed.ncbi.nlm.nih.gov/32523776/. DOI: 10.1186/s40942-020-00220-5.
55. Wolfrum P, Böhm EW, Lorenz K, et al. Short-term clinical outcomes of patients with diabetic macular edema following a therapy switch to Faricimab[J/OL]. J Clin Med, 2024, 13(15): 4508[2024-08-01]. https://pubmed.ncbi.nlm.nih.gov/39124774/. DOI: 10.3390/jcm13154508.
56. Cao C, Yu G, Deng Z. Early versus late switch to an intravitreal dexamethasone implant after failed anti-VEGF therapy for diabetic macular edema: a systematic review and meta-analysis[J]. Ophthalmic Res, 2025, 68(1): 360-371. DOI: 10.1159/000546682.
57. Busch C, Zur D, Fraser-Bell S, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema[J]. Acta Diabetol, 2018, 55(8): 789-796. DOI: 10.1007/s00592-018-1151-x.
58. Ruiz-Medrano J, Rodríguez-Leor R, Almazán E, et al. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: early versus late switch[J]. Eur J Ophthalmol, 2021, 31(3): 1135-1145. DOI: 10.1177/1120672120929960.
59. Kavoussi S, Nezgoda J, Chhablani J, et al. Early switch to the dexamethasone implant after sub-optimal response to anti-VEGF therapy for diabetic macular edema[J]. Invest Ophthalmol Vis Sci, 2021, 62(8): 1053.
60. 邓爱萍, 田润, 熊成, 等. 地塞米松玻璃体内植入剂早期联合康柏西普在抗血管内皮生长因子治疗反应不佳糖尿病性黄斑水肿中的应用[J]. 眼科新进展, 2023, 43(9): 722-726. DOI: 10.13389/j.cnki.rao.2023.0145.Deng AP, Tian R, Xiong C, et al. Application of intravitreal dexamethasone implant combined with conbercept in the treatment of diabetic macular edema with poor response to anti-vascular endothelial growth factor therapy[J]. Rec Adv Ophthalmol, 2023, 43(9): 722-726. DOI: 10.13389/j.cnki.rao.2023.0145.
61. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(10): 1904-1914. DOI: 10.1016/j.ophtha.2014.04.024.
62. Fraser-Bell S, Kang HK, Mitchell P, et al. Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study[J]. Br J Ophthalmol, 2023, 107(1): 72-78. DOI: 10.1136/bjophthalmol-2021-319070.
63. Kodjikian L, Baillif S, Couturier A, et al. Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: a national Delphi consensus study[J]. Eur J Ophthalmol, 2022, 32(5): 2845-2856. DOI: 10.1177/11206721211052852.
64. Rodríguez-Valdés PJ, Rehak M, Zur D, et al. GRAding of functional and anatomical response to dexamethasone implant in patients with diabetic macular edema: GRADE-DME Study[J/OL]. Sci Rep, 2021, 11(1): 4738[2021-02-06]. https://pubmed.ncbi.nlm.nih.gov/33637772/. DOI: 10.1038/s41598-020-79288-w.
65. Al-Khersan H, Hariprasad SM, Chhablani J, et al. Early response to intravitreal dexamethasone implant therapy in diabetic macular edema may predict visual outcome[J]. Am J Ophthalmol, 2017, 184: 121-128. DOI: 10.1016/j.ajo.2017.10.004.
66. Rosenblatt A, Udaondo P, Cunha-Vaz J, et al. ARTES Study Group. A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME Registry Study[J]. Ophthalmology, 2020, 127(3): 377-393. DOI: 10.1016/j.ophtha.2019.10.005.
67. Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(1): 29-38. DOI: 10.1001/jamaophthalmol.2017.4914.
68. Limon U. Early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema[J]. J Fr Ophtalmol, 2021, 44(6): 849-854. DOI: 10.1016/j.jfo.2020.08.033.
69. Lin TC, Chung YC, Hsu TK, et al. Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema[J]. Acta Diabetol, 2022, 59(4): 501-508. DOI: 10.1007/s00592-021-01824-5.
70. Zhao X, Lin Z, Long T, et al. Early combined conbercept and dexamethasone implant therapy for diabetic macular edema[J/OL]. Int Ophthalmol, 2025, 45(1): 267[2025-06-27]. https://pubmed.ncbi.nlm.nih.gov/40576850/. DOI: 10.1007/s10792-025-03646-8.
71. Chen J, Wang H, Qiu W. Intravitreal anti-vascular endothelial growth factor, laser photocoagulation, or combined therapy for diabetic macular edema: a systematic review and network meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1096105[2023-02-02]. https://pubmed.ncbi.nlm.nih.gov/36817588/. DOI: 10.3389/fendo.2023.1096105.
72. Yang X, Cao Y, Cao X, et al. Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: a Bayesian network meta-analysis[J]. Diabetes Obes Metab, 2025, 27(5): 2679-2689. DOI: 10.1111/dom.16270.
73. Hatano M, Wakuta M, Yamamoto K, et al. Use of ranibizumab for evaluating focal laser combination therapy for refractory diabetic macular edema patients: an exploratory study on the RELAND trials[J/OL]. Sci Rep. 2023, 13(1): 22965[2023-12-27]. https://pubmed.ncbi.nlm.nih.gov/38151499/. DOI: 10.1038/s41598-023-48665-6.
74. Lubis PM, Prabaniswara MP, Victor AA. Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: systematic review[J]. Indian J Ophthalmol, 2023, 71(11): 3448-3453. DOI: 10.4103/IJO.IJO_519_23.
75. Hosoya H, Ueta T, Hirasawa K, et al. Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis[J]. Graefe's Arch Clin Exp Ophthalmol, 2024, 262(10): 3073-3083. DOI: 10.1007/s00417-024-06460-7.
76. Xu D, Zhu T, Huang L, et al. Clinical efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a meta-analysis[J/OL]. Medicine (Baltimore), 2024, 103(5): e34583[2024-02-02]. https://pubmed.ncbi.nlm.nih.gov/38306515/. DOI: 10.1097/MD.0000000000034583.
77. Ma CC, Chen PH, Hsieh YH. Optimizing diabetic macular edema treatment: a meta-analysis of subthreshold micropulse laser and anti-vascular endothelial growth factor combination therapy[J/OL]. J Clin Med, 2024, 13(16): 4782[2024-08-14]. https://pubmed.ncbi.nlm.nih.gov/39200924/. DOI: 10.3390/jcm13164782.
78. Jiang Y, He W, Qi S. Evaluating the efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis[J/OL]. Front Endocrinol (Lausanne), 2025, 16: 1553311[2025-03-28]. https://pubmed.ncbi.nlm.nih.gov/40225323/. DOI: 10.3389/fendo.2025.1553311.
79. Çıtırık M. Nondamaging retinal laser therapy in recurrent diabetic macular edema after anti-VEGF injections[J]. Turk J Med Sci, 2021, 51(5): 2616-2620. DOI: 10.3906/sag-2007-304.
80. Elhamid AHA. Combined intravitreal dexamethasone implant and micropulse yellow laser for treatment of anti-VEGF resistant diabetic macular edema[J]. Open Ophthalmol J, 2017, 11: 164-172. DOI: 10.2174/1874364101711010164.
81. Wang M, Luan R, Liu B, et al. The anatomic and functional outcomes of ozurdex-aided vitrectomy in proliferative diabetic retinopathy[J]. Diabetes Metab Syndr Obes, 2024, 17: 1199-1213. DOI: 10.2147/DMSO.S445607.
82. Altun A, Kanar HS, Aki SF, et al. Effectiveness and safety of coadministration of intravitreal dexamethasone implant and silicone oil endotamponade for proliferative diabetic retinopathy with tractional diabetic macular edema[J]. J Ocul Pharmacol Ther, 2021, 37(2): 131-137. DOI: 10.1089/jop.2020.0079.
83. Kim KT, Jang JW, Kang SW, et al. Vitrectomy combined with intraoperative dexamethasone implant for the management of refractory diabetic macular edema[J]. Korean J Ophthalmol, 2019, 33(3): 249-258. DOI: 10.3341/kjo.2018.0100.
84. Jung YH, Lee Y. Efficacy of vitrectomy combined with an intraoperative dexamethasone implant in refractory diabetic macular edema[J]. Acta Diabetol, 2019, 56(6): 691-696. DOI: 10.1007/s00592-019-01305-w.
85. 惠延年. 糖尿病视网膜病: 糖尿病视网膜病变重新定义的术语[J]. 中华眼底病杂志, 2026, 42(1): 3-7. DOI: 10.3760/cma.j.cn511434-20251120-00515.Hui YN. Diabetic retinal disease: a redefined term for diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2026, 42(1): 3-7. DOI: 10.3760/cma.j.cn511434-20251120-00515.
86. Pei X, Li Z. Narrative review of comprehensive management strategies for diabetic retinopathy: interdisciplinary approaches and future perspectives[J/OL]. BMJ Public Health, 2025, 3(1): e001353[2025-01-16]. https://pubmed.ncbi.nlm.nih.gov/40017934/. DOI: 10.1136/bmjph-2024-001353.
87. Strain WD, Cos X, Prünte C. Considerations for management of patients with diabetic macular edema: optimizing treatment outcomes and minimizing safety concerns through interdisciplinary collaboration[J]. Diabetes Res Clin Pract, 2017, 126: 1-9. DOI: 10.1016/j.diabres.2017.01.013.

Chinese Journal of Ocular Fundus Diseases

Expert consensus on the clinical diagnosis and treatment path for diabetic macular edema in Zhejiang Province (2026)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content